share_log

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

納斯達克(NASDAQ:ITCI)在擴大其業務方面處於一個強勢的位置
Simply Wall St ·  08/26 21:08

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

哪怕一家業務虧損的公司,只要你能以合適的價格買入優質的企業,依然能獲得投資回報。例如,在成功開發新療法或發現礦物的生物科技或礦業勘探企業經常虧損數年。即便如此,無利可圖的公司仍然具備風險,因爲它們可能會燒光所有資金並面臨窘迫。

So should Intra-Cellular Therapies (NASDAQ:ITCI) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

因此,Intra-Cellular Therapies(納斯達克股票代碼:ITCI)的股東們是否應該擔心其現金燃燒?對於本文的目的,我們將現金燃燒定義爲公司每年用於資金增長的現金金額(也稱爲負的自由現金流)。首先,我們將通過將其現金燃燒與其現金儲備進行比較來判斷其現金儲備能夠支撐多久。

How Long Is Intra-Cellular Therapies' Cash Runway?

Intra-Cellular Therapies的現金儲備有多久?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2024, Intra-Cellular Therapies had cash of US$1.0b and no debt. Looking at the last year, the company burnt through US$61m. That means it had a cash runway of very many years as of June 2024. Notably, however, analysts think that Intra-Cellular Therapies will break even (at a free cash flow level) before then. If that happens, then the length of its cash runway, today, would become a moot point. You can see how its cash balance has changed over time in the image below.

公司的現金儲備能夠支撐的時間是通過將其現金儲備除以其現金燃燒來計算的。截至2024年6月,Intra-Cellular Therapies擁有10億美元的現金,沒有債務。回顧過去一年,公司的現金燃燒達到6100萬美元。這意味着截至2024年6月,它的現金儲備可以支撐非常多年。然而,分析師們認爲Intra-Cellular Therapies在那之前將會實現盈虧平衡(在自由現金流水平上)。如果發生這種情況,那麼今天其現金儲備的時間將變得無關緊要。您可以在下圖中看到其現金餘額隨時間的變化。

1724677734582
NasdaqGS:ITCI Debt to Equity History August 26th 2024
納斯達克ITCI公司的債務權益歷史2024年8月26日

How Well Is Intra-Cellular Therapies Growing?

Intra-Cellular Therapies的發展情況如何?

Happily, Intra-Cellular Therapies is travelling in the right direction when it comes to its cash burn, which is down 68% over the last year. And there's no doubt that the inspiriting revenue growth of 54% assisted in that improvement. Considering these factors, we're fairly impressed by its growth trajectory. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

令人高興的是,Intra-Cellular Therapies在現金燃燒方面走在正確的方向,過去一年下降了68%。毫無疑問,營業收入增長了54%,這有助於改善。考慮到這些因素,我們對其增長軌跡印象深刻。雖然過去值得研究,但最重要的是未來。因此,您可能希望看一看公司未來幾年預計增長多少。

How Hard Would It Be For Intra-Cellular Therapies To Raise More Cash For Growth?

對於Intra-Cellular Therapies來說,籌集更多資金用於增長有多困難?

While Intra-Cellular Therapies seems to be in a decent position, we reckon it is still worth thinking about how easily it could raise more cash, if that proved desirable. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

雖然Intra-Cellular Therapies似乎處於一個不錯的位置,但我們認爲如果有需要的話,考慮它如何輕鬆地籌集更多資金仍然是值得的。一般來說,上市公司可以通過發行股票或負債來籌集新的資金。上市公司所具有的主要優勢之一是可以向投資者出售股票以籌集資金並推動增長。我們可以將公司的現金流耗盡與其市值進行比較,以了解公司需要發行多少新股來籌集一年的運營資金。

Intra-Cellular Therapies' cash burn of US$61m is about 0.8% of its US$7.9b market capitalisation. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the cash by issuing a few shares.

Intra-Cellular Therapies斥資6100萬美元的現金流耗盡約佔其79億美元市值的0.8%。因此,它幾乎肯定可以通過借貸一些資金來爲另一個年度的增長提供資金,或者通過發行一些股票輕鬆籌集資金。

Is Intra-Cellular Therapies' Cash Burn A Worry?

Intra-Cellular Therapies的現金流耗盡是一個令人擔憂的問題嗎?

As you can probably tell by now, we're not too worried about Intra-Cellular Therapies' cash burn. In particular, we think its revenue growth stands out as evidence that the company is well on top of its spending. And even its cash burn reduction was very encouraging. It's clearly very positive to see that analysts are forecasting the company will break even fairly soon. Taking all the factors in this report into account, we're not at all worried about its cash burn, as the business appears well capitalized to spend as needs be. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 1 warning sign for Intra-Cellular Therapies that potential shareholders should take into account before putting money into a stock.

正如你現在可能已經發現的那樣,我們對Intra-Cellular Therapies的現金流耗盡並不太擔心。特別是,我們認爲其營業收入增長突出,這證明了該公司在控制支出方面表現出色。即使是現金流耗盡的減少也是非常令人鼓舞的。很明顯,看到分析師們預測該公司將很快實現盈虧平衡是非常積極的。綜合考慮本報告中的所有因素,我們對其現金流耗盡一點也不擔心,因爲該業務似乎有足夠的資本支出。在投資股票之前,讀者需要對業務風險有一個明確的了解,而我們在Intra-Cellular Therapies中發現了1個需要潛在股東注意的警示信號。

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

如果您希望查詢其他基本面更好的公司,則不要錯過具有高淨資產回報率和低債務的有趣公司免費列表,或者這個預計所有股票都會增長的股票列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論